Model-Based Drug Development for Diabetes Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 411
Special Issue Editors
Interests: mathematical modeling and simulation; pharmacokinetics (PK) and pharmacodynamics (PD); population PK (popPK); physiologically based PK (PBPK); quantitative system pharmacology (QSP); diabetes pathophysiology; diabetes technology
Interests: mathematical modeling and simulation; pharmacokinetics (PK); pharmacodynamics (PD); population PK (popPK); physiologically based PK (PBPK); quantitative system pharmacology (QSP); diabetes pathophysiology; diabetes technology
Special Issue Information
Dear Colleagues,
Mathematical modeling and simulation has become fundamental in all the phases of drug development, for better understanding drug mechanisms of action and effects and supporting decision making and personalized medicine in a time- and cost-effective way. Different modeling and simulation approaches are suitable depeding upon the specific aim, ranging from high-detailed mechanistic models based on system characteristics and in vitro/preclinical data to predict clinical outcomes (“bottom-up” approach), as well as more semi-mechanistic/empirical models based on observed clinical data to predict system characteristics and variability (“top-down” approach), to a combination of the two.
Targeting the field of diabetes, mathematical modeling and simulation has helped in developing new insulin molecules, other oral and injectable drugs. as well as testing their safety and efficacy in the target populations.
This Special Issue invites research and review articles on the use of mathematical modeling and simulation as a tool for drug development and testing in the field of diabetes treatment. Articles based on in vitro/preclinical to clinical data exploiting modeling and simulation tools for designing first-in-human trials, predicting drug-to-drug interactions, quantifying factors affecting variability, as well as simulating new delivery systems, and therapeutic treatments and dosing regimens in the target populations of novel or repurpose drugs are some of the research areas that this Special Issue aims to include.
Dr. Michele Schiavon
Dr. Roberto Visentin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mathematical modeling and simulation
- type 1 diabetes
- type 2 diabetes
- insulin
- diabetic medications
- oral drugs
- injectable drugs
- pharmacokinetic (PK) models
- pharmacodynamics (PD) models
- physiologically based PK/PD (PBPK/PD) models
- quantitative system pharmacology (QSP)
- population PK/PD (popPK/PD)
- in silico trials
